Synartro is a Swedish life science company developing local injection treatments to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our novel delivery technology with existing proven drugs.
Our lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). This disease leaves up to 50% of patients without adequate pain relief.
Bengt Lindqvist, part of the team behind the hyaluronic acid substance Healon from Pharmacia, is the inventor of our patented hyaluronan-based drug delivery platform. After the initial discovery, he teamed up with other skilled chemists to commence development of the compound SYN321, where diclofenac is linked to the drug delivery platform. In 2013, an animal study showed that SYN321 provided a sustained release of diclofenac in knee joints of horses, without observed side effects.
In 2020, a US patent was granted for the drug delivery platform. Since then, development activities have intensified.
Technology & Portfolio
Unique drug delivery technology
Synartro develops improved injection treatments using a patented drug delivery technology that enables a sustained drug release. By locally injecting the treatment, a very low dose of the active substance is needed. For other indications where local slow release of compounds with systemic safety concerns is beneficial, our delivery technology could provide significant improvement.
Lead program, SYN321
Drug candidate SYN321 is an intraarticular injection, containing diclofenac and hyaluronan, in development for the treatment of knee OA. It is the unique binding between diclofenac and hyaluronan that enable therapeutic benefits of SYN321 such as reduced side effects, prolonged pain relief as well as reduction of inflammation and pain. Compared with other treatments, considerably less SYN321 substance is needed for desired efficacy. SYN321 also has disease-modifying potential, which could slow down or, in best case, stop the disease progression entirely.
SYN321 has the potential to become the preferred second-line treatment for knee OA.
The next step for SYN321 is a first-in-human trial. This trial will focus on safety and exploratory efficacy of SYN321. Synartro plans to manufacture product and file for approval for the trial with relevant authorities in 2022.
In the preclinical stage of SYN321 a study in horses was completed at the Swedish University of Agricultural Sciences, SLU. The results from the study showed very good tolerability and favorable pharmacokinetics. The preclinical program has covered several studies giving further information on the characteristics of SYN321.
Other steps that have been performed are to manufacture the substance under GMP conditions and toxicological safety studies.
The patent filed by Synartro in 2015 was initially approved in the US in May 2020 and in Europe in December 2021. The patent is a compound patent, covering the unique platform of hyaluronan and a linker, that can be connected to different pharmaceutical active substances. Thus, the patent protects not only SYN321, but also other compounds based on the platform.
The patent is valid until 2035, with a possible extension of five years. It is the company’s assessment that the patent provides strong immaterial protection.
About knee OA
OA is a chronic, slowly progressive, joint disease caused by the breakdown of joint cartilage, which leads to pain, stiffness, and reduced motion. OA is generally diagnosed in people over 40 years of age and mainly affects the knees, hips, and hands. Women have a higher risk of becoming affected by OA, as well as individuals with physically stressful jobs or those affected by obesity.
Around 320 million people are estimated to be affected by osteoarthritis globally, a number which is expected to have increased to 370 million by 2028. The global prevalence of osteoarthritis is 23% in individuals aged 40 and over). Roughly 24 million patients are estimated to receive drug treatment for knee OA. An early diagnosis generally yields best treatment outcomes. There are four disease stages: minor, mild, moderate and severe.
There is no cure for osteoarthritis. At diagnosis, knee OA is commonly treated with mild analgesics and physiotherapy where the key focus is pain relief and increasing mobility. The second treatment approach includes the use of analgesics (NSAIDs and opioids), intraarticular steroids, and hyaluronan injections.
With 50% of treated patients left with inadequate pain relief or side effects from the treatment, there is a huge unmet clinical need for novel drugs that can increase the level and duration of pain relief without causing systemic side effects.
Based on the current standards, the novel combination of SYN321 with demonstrated favorable safety profile in preclinical trials is well-positioned as a second-line treatment for OA.
Current treatment steps
At early diagnosis of mild knee osteoarthritis, the patient receives instruction to do physical therapy and use paracetamol (rescue analgesic). If symptoms remain, topical NSAIDs and regular exercise are prescribed.
Step 2 – novel SYN321 therapy
As a second-line treatment intermittent or continuous oral NSAIDs (non-selective, COX-2 selective, naproxen, etc.) are given as symptom reliever. If additional treatment is needed, the patient can receive either intraarticular hyaluronan or intraarticular corticosteroids. This step is where use of SYN321 could be initiated.
For the moderate progression stage of knee osteoarthritis, the symptoms and pain from the breakdown of joint cartilage can be relieved with weak and short-term opioids and continued injections as in step 2.
Once the disease has reached the point of completely broken-down joint cartilage, none of the previous treatment steps can reduce the symptoms enough. The final treatment option for severe osteoarthritis is joint replacement surgery.
There is currently a major demand for osteoarthritis treatments with improved safety and efficacy profiles within the medical community as well as a strong desire to avoid surgery and opioids. The increasing interest in intraarticular combinations offering these benefits is making the SYN321 a great candidate for future treatments.
SYN321 has shown beneficial properties with a favorable side effect profile and potential for long-term pain relief in animal studies. The novel combination therapy of SYN321 could provide patients the ability to live an active life again. A patent has been approved for the unique binding between diclofenac and hyaluronan in SYN321, which offers several competitive advantages including a better side-effect profile compared to competing injectables, opioids, oral diclofenac and other NSAIDs.
There is a clear trend towards injection treatments instead of opioids and NSAIDs due to their side effects. Injections with longer duration are gaining market share. The number of treated osteoarthritis patients are growing with the aging society and an increasingly overweight population.
The annual market opportunity for SYN321 is estimated between $324M – $700M looking solely at the seven major markets: France, Germany, Italy, Japan, Spain, UK, and the US. Synartro’s current focus is on Europe and the US. The market is expected to grow with a need for better treatments.
Board of Directors
PhD & Chairman
Fredrik has held several positions at Pharmacia, Biovitrum and Personal Chemistry. He is also founder of six chemistry or life science related companies, where OT Chemistry was acquired by Recipharm in June 2015. Expert in CMC.
Mats is the former Executive Senior Vice President Business Development and partner at SHL Group, the world’s largest privately owned MedTech company. He has more than 30 years’ experience from the pharma and MedTech industry and has a vast network all over the world.
Lars has more than 30 years of experience in regulatory affairs and drug development. He has worked at the Swedish MPA as well as Schering and Kabi Pharmacia. In 1992 he founded Scandinavian Regulatory Services and has been leading it ever since.
+46 (0)73 433 60 25
CFO & Investor Relations
+46 (0)76 027 44 27
Synartro is a Swedish life science company developing local injection treatments that provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our novel delivery technology with existing proven drugs.
The initial focus area is knee OA, a disease with significant demand for treatments with improved efficacy and safety profiles for the growing patient population.
The company is currently finalizing its preparations to move into clinical phase.
The company is seeking investments to enable continued development of its promising lead program SYN321.
For further information, please get in touch with Mia Brundin, CEO.
Synartro has been granted regulatory and ethical approval for the first clinical trial of lead compound SYN321 for treatment of symptomatic knee osteoarthritis
27 April 2023 – Synartro announces that the company has been granted approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the phase 1/2a first-in-human clinical study of the investigational drug candidate SYN321.
Synartro prepares for first clinical trial of lead compound SYN321 for treatment of symptomatic knee osteoarthritis
31 January 2023 – Synartro announced today that the company has submitted a clinical trial application to the Swedish Medical Products Agency and the Swedish Ethical Review Authority, for a phase 1/2a first-in-human clinical study of investigational drug candidate SYN321.
Synartro granted European patent
17 February 2022 – Synartro’s patent application for its drug delivery platform has been granted by the European Patent Office. The patent strengthens the position of the company’s lead candidate SYN321, which is developed for treatment of knee osteoarthritis. The granted patent also protects further development within other areas and indications based on the platform.
Synartro tar in 34 Mkr inför studie på patienter med knäartros
25 oktober 2021 – Synartro, som utvecklar nytt läkemedel mot artros har tagit in 34 Mkr i en nyemission. Bolagets största aktieägare, investmentbolaget Linc, utökade sin ägarandel ytterligare. Kapitalet ska användas till att genomföra den första kliniska studien i människa med bolagets läkemedelskandidat SYN321.
Goda inledande resultat i Synartros prekliniska utveckling av SYN321
5 oktober 2021 – Synartro, som utvecklar ett nytt läkemedel för behandling av artros, meddelar att de inledande toxikologi- och säkerhetsstudierna för läkemedelskandidaten SYN321 har genomförts med goda resultat. Utvecklingsarbetet fortsätter därmed för att påbörja klinisk prövning under 2022.
Synartro rekryterar CFO och förstärker projektteamet inför start av kliniska studier
15 maj 2021 – Bioteknikbolaget Synartro växlar upp inför nästa steg i utvecklingen av bolagets kandidat SYN321 och rekryterar Magnus Hurst som CFO samt Eva Arlander som har gedigen erfarenhet från läkemedelsbranschen och kliniskt utvecklingsarbete.
Synartro har fått positivt besked inför toxikologiska säkerhetsstudier i höst
31 mars 2021 – Synartro har efter vetenskaplig rådgivning med Läkemedelsverket beslutat att under hösten 2021 inleda toxikologiska säkerhetsstudier med läkemedelskandidaten SYN321 för behandling av knäartros. Studierna kan vara tillräckliga för att starta nästa fas i läkemedelsutvecklingen – kliniska studier med SYN321 i patienter.
Synartro rapporterar positivt utfall från effektstudie av SYN321
22 December 2020 – Synartro, som utvecklar ett nytt läkemedel för behandling av artros, har framgångsrikt slutfört en preklinisk effektstudie av kandidaten SYN321 i råtta med knäartros. Studieresultaten visar effekt av SYN321 avseende smärta och viktuppgång trots väsentligt lägre dos diklofenak. Bolaget går därmed vidare med säkerhetsstudier för att därefter kunna göra en första studie i människa.
Synartro presents at Redeye and Sciety Life Science Unlisted 2020
On 2nd of December, Synartro was invited to present at Redeye and Sciety Life Science Unlisted 2020. Please click here to access our presentation by Mia Brundin, CEO of Synartro.
Fulltecknad nyemission om 17 MSEK genomförd
Synartro meddelar att bolaget har genomfört en fulltecknad nyemission om 17 miljoner kronor tillsammans med investeringsnätverket Sciety. Emissionen fulltecknades den 2 oktober på endast fyra dagar. Kapitaltillskottet ska användas för att slutföra det prekliniska arbetet med kandidaten SYN321 för behandling av knäartros, och innefattar bland annat CMC (kemi, tillverkning och kvalitetskontroll av kandidaten) och toxikologiska studier.
Synartro får nytt patent i USA
29 september 2020 – Synartros patentansökan avseende bolagets plattform för läkemedelsadministration beviljas i USA. Med patentet stärker bolaget sin position för kandidaten SYN321 som utvecklas för behandling av knäartros i människa men också möjligheterna till utlicensiering inom andra områden och indikationer.
Synartro genomför fulltecknad nyemission inför artrosstudie
5 maj 2020 – Synartro, ett svenskt bioteknikföretag fokuserat på utveckling av en patentsökt teknologiplattform för att förbättra effekt och säkerhet av beprövade substanser, med målsättning att kunna erbjuda artrospatienter en lokal och säker behandling som alternativ till behandling med opioider, injicerad hyaluronsyra samt orala NSAID-preparat, meddelade idag att bolaget genomfört en fulltecknad nyemission.
Synartro har genomfört en nyemission tillsammans med life science investerarnätverket Sciety. Kapitalet syftar till att färdigställa tillverkningen av SYN321 hos bolagets tillverkningspartner Recipharm för att inleda en artrosstudie tillsammans med ett externt, oberoende kontraktslabb i en industrivaliderad sjukdomsmodell. Studien besvarar en rad viktiga utvecklingsfrågor och underleverantören har kontrakterats efter en systematisk utvärdering av olika artrosmodeller.
Mia Brundin announced as new CEO of Synartro
20 April 2020 – Mia Brundin has over 20 years of leadership experience from international business development and commercial roles at companies such as AstraZeneca, Recip and Meda. Today, Mia is the Country Manager Sweden for Mylan, one of the largest global healthcare companies. Mia holds a Master of Science in Business Administration and Economics, International Business Program, from Linköping University.
“It is with great excitement and enthusiasm that the Board today announces that Mia Brundin has accepted the role as CEO of Synartro,” says Fredrik Lehmann, Synartro Chairman of the Board. “Mia has led several successful development projects as well as international launches and, with her impressive track record and broad experience in international commercialization and leadership, we look forward to continuing the development of our lead program SYN321 as well as exploring further opportunities for Synartro.”
Mia Brundin will start her new leadership position as the CEO of Synartro on August 1, 2020. Until that time, Monika Vedin, current CEO, will remain in her position.